Fischer Medical Ventures Ltd has informed the exchange on the receipt of Monitoring Agency Report for the quarter ended 30.06.2025
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures Limited has filed the Monitoring Agency Report for Q1 FY26 (quarter ended June 30, 2025), prepared by Infomerics Valuation and Rating Limited, covering the use of Rs. 358.46 crore raised through a preferential issue of equity shares and fully convertible warrants. Of the Rs. 270.40 crore actually received so far (1.03 crore equity shares allotted at Rs. 234 each plus 25% warrant application money), Rs. 269.20 crore has been utilized and only Rs. 1.20 crore remains unutilized. The funds were deployed toward growth objectives (investments in wholly owned subsidiaries, Rs. 268.84 crore planned) and general corporate purposes, including Rs. 1.20 crore used to repay a loan to promoter-group entity Time Medical International Ventures (India) Private Limited. The Monitoring Agency confirmed zero deviation from disclosed objects, no change in means of finance, and no delays in implementation of the stated objects.
This is a routine SEBI compliance filing that confirms disciplined and on-track use of the preferential issue proceeds, which is a mildly positive governance signal for shareholders. No material impact on the stock is expected, though the report enhances transparency on how the recently raised capital is being put to work.